Lutetium-177 DOTATATE — Drug Monograph

Brand names: Lutathera

Drug class: Radiopharmaceutical

Mechanism of Action

Peptide receptor radionuclide therapy (PRRT). DOTATATE (DOTA-Tyr³-octreotate) is a somatostatin analogue that binds with high affinity to somatostatin receptor subtype 2 (SSTR2), which is overexpressed on the surface of well-differentiated neuroendocrine tumor cells. Upon binding and internalization, the linked radioisotope lutetium-177 (¹⁷⁷Lu) — a beta-particle and gamma-ray emitter with a physical half-life of ~6.6 days — delivers targeted radiation directly to tumor cells and adjacent microenvironment (crossfire effect). Beta particles cause DNA double-strand breaks and apoptosis in…

FDA Indications

• Somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs — FDA approved January 2018 (based on NETTER-1 Phase 3 trial)

Common Side Effects

• Nausea and vomiting (related to amino acid infusion — premedicate with antiemetics)
• Fatigue
• Abdominal pain
• Anemia, lymphopenia
• Decreased appetite
• Diarrhea
• Elevated liver enzymes (transient)

Clinical Pearl

Lutathera is the only FDA-approved PRRT agent in the US (as of 2025). The pivotal NETTER-1 trial demonstrated a 79% reduction in risk of disease progression or death (HR 0.21) vs. high-dose octreotide LAR in midgut SSTR+ NETs, establishing PRRT as a cornerstone of advanced NET therapy. The NETTER-2 Phase 3 trial (NEJM 2024) extended this evidence to G2/G3 SSTR+ GEP-NETs — including pancreatic NETs (pNETs) — demonstrating a median PFS of 22.8 vs. 8.5 months (HR 0.28, p<0.0001) vs. high-dose…

Related Therapies & Mechanisms

• Lutetium Lu 177 dotatate (Lutathera) — Radiopharmaceutical · NET
• Lutetium Lu 177 Vipivotide Tetraxetan (Pluvicto) — Radiopharmaceutical
• Radium-223 Dichloride (Xofigo) — Radiopharmaceutical
• Capecitabine (Xeloda) — NET